the predictive value of treatment response after neoadjuvant therapy
Published 1 year ago • 437 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
1:40
predicting pathological complete response in breast cancer
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
2:32
the rationale for neoadjuvant therapy for breast cancer
-
2:17
loss of her2 after neoadjuvant treatment of her2 early bc
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting
-
17:42
what do we do after complete response to neoadjuvant therapy?
-
5:21
optimal neoadjuvant and adjuvant therapy for patients with early tnbc
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
2:13
changes in tumour biomarkers after neoadjuvant chemotherapy in breast cancer
-
7:15
characterizing the immune microenvironment before and following anti-her2 neoadjuvant therapy
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
7:15
pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...
-
1:38
compassher2-pcr: de-escalation of neoadjuvant chemotherapy for breast cancer
-
3:39
steps for patients who do not receive complete response after neoadjuvant therapy
-
1:33
role & evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy
-
5:46
value of circulating tumor dna after neoadjuvant chemotherapy for triple negative breast cancer
-
6:55
the prognostic value of ctdna in nsclc treated with neoadjuvant chemoimmunotherapy